Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments

• CHIEN JY, MOHUTSKY MA, WRIGHTON SA: Physiological approaches to the prediction of drug–drug interactions in study populations. Curr. Drug Metab. (2003) 4(5):347-356.
   PubMed Web of Science ®Google Scholar
• HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The International Classification of Headache Disorders, 2nd edition. Cephalalgia (2004) 24(Suppl. 1):9-160.
   PubMed Web of Science ®Google Scholar
• HENRY P, AURAY JP, GANDIN AF et al.: Prevalence and clinical characteristics of migraine in France. Neurology (2002) 59:232-237.
   PubMed Web of Science ®Google Scholar
• MACGREGOR EA, BRANDES J, EIKERMANN A: Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache (2003) 43:19-26.
   PubMed Web of Science ®Google Scholar
• JENSEN R: Diagnosis, epidemiology, and impact of tension-type headache. Curr. Pain Headache Rep. (2003) 7:455-459.
   PubMedGoogle Scholar
• SJAASTAD O, BAKKETEIG LS: Cluster headache prevalence. Vågå study of headache epidemiology. Cephalalgia (2003) 23:528-533.
   PubMed Web of Science ®Google Scholar
• FINKEL AG: Epidemiology of cluster headache. Curr. Pain Headache Rep. (2003) 7:144-149.
   PubMedGoogle Scholar
• DIAMOND ML, WENZEL RG, NISSAN GR: Optimizing migraine therapy: evidence-based and patient-centered care. Expert Rev. Neurother. (2006) 6(6):911-919.
   PubMed Web of Science ®Google Scholar
• SCHER AI, BIGAL ME, LIPTON RB: Comorbidity of migraine. Curr. Opin. Neurol. (2005) 18:305-310.
   PubMed Web of Science ®Google Scholar
• PRYSE-PHILLIPS WEM, DODICK DW, EDMEADS JG et al.: Guidelines for the diagnosis and management of migraine in clinical practice. Can. Med. Assoc. J. (1997) 156:1273-1287.
   PubMed Web of Science ®Google Scholar
• DANISH NEUROLOGICAL SOCIETY AND THE DANISH HEADACHE SOCIETY: Guidelines for the management of headache. Cephalalgia (1998) 18:9-22.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD: Practice parameter: evidenced-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Committee of the American Academy of Neurology. Neurology (2000) 55:754-763.
   PubMed Web of Science ®Google Scholar
• ITALIAN SOCIETY FOR THE STUDY OF HEADACHES: Diagnostic and therapeutic guidelines for migraine and cluster headache. J. Headache Pain (2001) 2:105-192.
   Google Scholar
• AMERICAN ACADEMY OF FAMILY PHYSICIANS AND THE AMERICAN COLLEGE OF PHYSICIANS – AMERICAN SOCIETY OF INTERNAL MEDICINE: Clinical guidelines for the pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. (2002) 137:840-849.
   PubMed Web of Science ®Google Scholar
• GERAUD G, LANTERI-MINET M, LUCAS C, VALADE D; on behalf of the FRENCH SOCIETY for the STUDY of MIGRAINE HEADACHE (SFEMC): French guidelines for the diagnosis and managements of migraine in adults and children. Clin. Ther. (2004) 26(8):1305-1318.
   PubMed Web of Science ®Google Scholar
• SCHUURMANS A, VAN-WEEL C: Pharmacological treatment of migraine. Comparison of guidelines. Can. Fam. Physician (2005) 51:838-843.
   PubMed Web of Science ®Google Scholar
• BREIMER DD, DANHOF M: Relevance of the application of pharmacokinetic–pharmacodynamic modelling concepts in drug development. The ‘Wooden shoe’ paradigm. Clin. Pharmacokinet. (1997) 32(4):259-267.
   PubMed Web of Science ®Google Scholar
• LEUCUTA SE, VLASE L: Pharmacokinetics and metabolic drug interactions. Curr. Clin. Pharmacol. (2006) 1:5-20.
   PubMedGoogle Scholar
• MA MK, WOO MH, MCLEOD HL: Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. (2002) 59:2061-2069.
   PubMed Web of Science ®Google Scholar
• WILKINSON GR: Drug metabolism and variability among patients in drug response. N. Engl. J. Med. (2005) 352(21):2211-2221.
   PubMed Web of Science ®Google Scholar
• TANAKA E: Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes. J. Clin. Pharm. Ther. (1998) 23(6):403-416.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG PF: Characteristics and common properties of inhibitors, inducers and activators of CYP enzymes. Drug Metab. Rev. (2002) 34:17-35.
   PubMed Web of Science ®Google Scholar
• LI AP, MAUREL P, GOMEZ-LECHON MJ, CHENG LC, JURIMA-ROMET M: Preclinical evaluation of drug–drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interact. (1997) 107(1-2):5-16.
   PubMed Web of Science ®Google Scholar
• BACHMAN KA, LEWIS JD: Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann. Pharmacother. (2005) 39(6):1064-1072.
   PubMed Web of Science ®Google Scholar
• FABER MS, JETTER A, FUHR U: Assessment of CYP 1A2 activity in clinical practice: why, how, and when? Basic Clin. Pharmacol. Toxicol. (2005) 97(3):125-134.
   PubMed Web of Science ®Google Scholar
• INGELMAN-SUNDBERG M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. (2005) 5(1):6-13.
   PubMed Web of Science ®Google Scholar
• TOES MJ, JONES AL, PRESCOTT L: Drug interactions with paracetamol. Am. J. Ther. (2005) 12(1):56-66.
   PubMed Web of Science ®Google Scholar
• KIRCHHEINER J, BROCKMOLLER J: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. (2005) 77(1):1-16.
   PubMed Web of Science ®Google Scholar
• DRESSER GK, SPENCE JD, BAILEY DG: Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 inhibition. Clin. Pharmacokinet. (2000) 38(1):41-57.
   PubMed Web of Science ®Google Scholar
• KIANG TK, ENSOM MH, CHANG TK: UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. (2005) 106(1):97-132.
   PubMed Web of Science ®Google Scholar
• VAN WYK M, SOMMERS DK, MONCRIEFF J: Effect of enhancement and antagonism of 5-hydroxytryptamine activity on the influence of metoclopramide on gastric emptying. Digestion (1993) 54(11):40-43.
   Google Scholar
• FINLEY PR, WARNER MD, PEABODY CA: Clinical relevance of drug interactions with lithium. Clin. Pharmacokinet. (1995) 29(3):172-191.
   PubMed Web of Science ®Google Scholar
• WADHWA NK, SCHROEDER TJ, O’FLAHERTY E et al.: The effect of oral metoclopramide on the absorption of cyclosporine. Transplant. Proc. (1987) 19:1730-1733.
   PubMed Web of Science ®Google Scholar
• MANZI SF, SHANNON M: Drug interactions – a review. Clin. Ped. Emerg. Med. (2005) 6:93-102.
   Google Scholar
• TANIGAWARA Y: Role of P-glycoprotein in drug disposition. Ther. Drug Monit. (2000) 22(1):137-140.
   PubMed Web of Science ®Google Scholar
• TROOST J, LINDENMAIER H, HAEFELI WE, WEISS: Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. J. Mol. Pharmacol. (2004) 66(5):1332-1339.
   PubMed Web of Science ®Google Scholar
• BRUNNER M, LANGER O, SUNDER-PLASSMANN R et al.: Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin. Pharmacol. Ther. (2005) 78(2):182-190.
   PubMed Web of Science ®Google Scholar
• BENET LZ, HOENER BA: Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. (2002) 71(3):115-121.
   PubMed Web of Science ®Google Scholar
• FRÖLICH JC: A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol. Sci. (1997) 18(1):30-34.
   PubMed Web of Science ®Google Scholar
• RODRIGUES AD: Impact of CYP2C9 genotype on pharmacokinetics: are all ciclooxygenase inhibitors the same? Drug Metab. Dispos. (2005) 33:1567-1575.
   PubMed Web of Science ®Google Scholar
• VERBEEK RK: Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. (1990) 19(1):44-66.
   PubMed Web of Science ®Google Scholar
• HOBBS DC, TWOMEY TM: Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. J. Clin. Pharmacol. (1979) 19(5-6):270-281.
   PubMed Web of Science ®Google Scholar
• DAY RO, GRAHAM GG, WILLIAMS KM et al.: Clinical pharmacology of non-steroidal anti-inflammatory drugs. Pharmacol. Ther. (1987) 33:383-443.
   PubMed Web of Science ®Google Scholar
• DIENER HC, LAMPL C, REIMNITZ P, VOELKER M: Aspirin in the treatment of acute migraine attacks. Review. Expert Rev. Neurother. (2006) 6(4):563-573.
   PubMedGoogle Scholar
• SILBERSTEIN SD, ARMELLINO JJ, HOFFMAN HD et al.: Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies. Clin. Ther. (1999) 21(3):475-491.
   PubMed Web of Science ®Google Scholar
• MINERS JO, ATTWOOD J, BIRKETT DJ: Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen’s metabolic pathways. Clin. Pharmacol. Ther. (1984) 35(4):480-486.
   PubMed Web of Science ®Google Scholar
• BUCLEY NA, SRINIVASAN J: Should a lower treatment line be used when treating paracetamol poisoning in patients with chronic alcoholism?: a case for. Drug Saf. (2002) 25(9):619-624.
   PubMed Web of Science ®Google Scholar
• YEH KC: Pharmacokinetic overview of indomethacin and sustained-release indomethacin. Am. J. Med. (1985) 79(4C):3-12.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA M, INOUE T, SHIMADA N, TOKUDOME S, YAMAMOTO T, KUROIWA Y: Cytochrome P4502C9 catalyzes indomethacin. O-demethylation in human liver microsomes. Drug Metab. Dispos. (1998) 26(3):261-266.
   PubMed Web of Science ®Google Scholar
• DODICK DW: Indomethacin-responsive headache syndromes. Curr. Pain Headache Rep. (2004) 8(1):19-26.
   PubMedGoogle Scholar
• TFELT-HANSEN P, DE VRIES P, SAFENA PR: Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 60(6):1259-1287.
   PubMed Web of Science ®Google Scholar
• DODICK DW, GERAUD G, KEYWOOD C, SENARD JM: Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache (2003) 43(4):376-388.
   PubMed Web of Science ®Google Scholar
• DODICK DW, MARTIN V: Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia (2004) 24(6):417-424.
   PubMed Web of Science ®Google Scholar
• FERRARI A, STERNIERI E, FERRARIS E et al.: Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol. Res. (2003) 48(1):1-9.
   PubMed Web of Science ®Google Scholar
• MC-ENROE JD, FLEISHAKER JC: Clinical pharmacokinetic of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin. Pharmacokinet. (2005) 44(3):237-246.
   PubMed Web of Science ®Google Scholar
• COLE P, RABASSEDA X: Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist. Drugs Today (2001) 37(3):159-171.
   PubMedGoogle Scholar
• COMER MB: Pharmacology of the selective 5-HT1B/1D agonist, frovatriptan. Headache (2002) 42(Suppl. 2):47-53.
   PubMed Web of Science ®Google Scholar
• KEMPSFORD RD, BAILLE P, FUSEAU E: Oral naratriptan (2.5 – 10 mg) demonstrate dose-proportional pharmacokinetics. Cephalalgia (1997) 17:408.
   Google Scholar
• GOLDBERG MR, LEE Y, VYAS KP et al.: Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single-and multiple-dose tolerability and pharmacokinetics in healthy subjects. J. Clin. Pharmacol. (2000) 40:74-83.
   PubMed Web of Science ®Google Scholar
• DUQUESNOY C, MAMET JP, SUMMER D et al.: Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur. J. Pharm. Sci. (1998) 6:99-104.
   PubMed Web of Science ®Google Scholar
• ROLAN PE, MARTIN GR: Zolmitriptan: a new acute treatment for migraine. Expert Opin. Invest. Drugs (1998) 7:633-652.
   PubMedGoogle Scholar
• TFELT-HANSEN P, SAXENA PR, DAHLOF C et al.: Ergotamine in the acute treatment of migraine; a review and European consensus. Brain (2000) 123:9-18.
   PubMed Web of Science ®Google Scholar
• AUSBAND SC, GOODMAN PE: Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. J. Emerg. Med. (2001) 21(4):411-413.
   PubMed Web of Science ®Google Scholar
• PERRIN VL: Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin. Pharmacokinet. (1985) 10:334-352.
   PubMed Web of Science ®Google Scholar
• COLMAN I, BROWN MD, INNES GD, GRAFSTEIN E, ROBERTS TE, ROWE BH: Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann. Emerg. Med. (2005) 45(4):393-401.
   PubMed Web of Science ®Google Scholar
• MARKLEY HG: Chronic headache: appropriate use of opiate analgesics. Neurology (1994) 44(3):S18-S24.
   Google Scholar
• KUHLMAN JJ Jr LALANI S, MAGLUILO J Jr et al.: Human pharmacokinetics of intravenous, sublingual and buccal buprenorphine. J. Anal. Toxicol. (1996) 20:369-378.
   PubMed Web of Science ®Google Scholar
• WERMELING DP, MILLER JL, ARCHER SM, RAYENS MK, RUDY AC: Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps. J. Clin. Pharmacol. (2005) 45(8):969-973.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DG, HATCH DJ, HOWARD RF: Codeine phosphate in paediatric medicine. Br. J. Anaesth. (2001) 86(3):413-421.
   PubMed Web of Science ®Google Scholar
• YUE QY, SAWE J: Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur. J. Clin. Pharmacol. (1997) 52:41-47.
   PubMed Web of Science ®Google Scholar
• HEISKANEN TE, RUISMAKI PM, SEPPALA TA et al.: Morphine or oxycodone in cancer pain? Acta Oncol. (2000) 39(8):941-947.
   PubMed Web of Science ®Google Scholar
• INTURRISI CE: Clinical pharmacology of opioids for pain. Clin. J. Pain. (2002) 18(Suppl. 4):3-13.
   PubMed Web of Science ®Google Scholar
• FERRARI A, COCCIA C, BERTOLINI A, STERNIERI E: Methadone-metabolism, pharmacokinetics and interactions. Pharmacol. Res. (2004) 50:551-559.
   PubMed Web of Science ®Google Scholar
• LURCOTT G: The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesth. Prog. (1999) 45:154-156.
   Google Scholar
• PEARSON RM: Pharmacokinetics of propoxyphene. Hum. Toxicol. (1984) 3(Suppl.):37S-40S.
   PubMedGoogle Scholar
• GROND S, SABLOTZKI A: Clinical pharmacology of tramadol. Clin. Pharmacokinet. (2004) 43(13):879-923.
   PubMed Web of Science ®Google Scholar
• LADER M: Clinical pharmacology of antipsychotic drugs. J. Int. Med. Res. (1989) 17(1):1-6.
   PubMed Web of Science ®Google Scholar
• VALOTI M, FROSINI M, PALMI M et al.: N-dealkylation of chlorimipramine and chlorpromazine by rat liver microsomal cytochrome P450 isoenzymes. J. Pharm. Pharmacol. (1998) 50(9):1005-1011.
   PubMed Web of Science ®Google Scholar
• BIGAL ME, BORDINI CA, SPECIALI JG: Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J. Emerg. Med. (2002) 23(2):141-148.
   PubMed Web of Science ®Google Scholar
• BROGDEN RN, CARMINE AA, HEEL RC et al.: Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs (1982) 24:360-400.
   PubMed Web of Science ®Google Scholar
• COLMAN I, BROWN MD, INNES GD, GRAFSTEIN E, ROBERTS TE, ROWE BH: Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ (2004) 329:1369-1373.
   PubMed Web of Science ®Google Scholar
• O’CONNELL ME, AWNI WM, GOODMAN M et al.: Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. J. Clin. Pharmacol. (1987) 27(8):610-614.
   PubMed Web of Science ®Google Scholar
• HATLEBAKK JG, BERSTAD A: Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacokinet. (1996) 31:386-406.
   PubMed Web of Science ®Google Scholar
• DESTA Z, WU CM, MOROCHO AM et al.: The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab. Dispos. (2002) 30(3):336-343.
   PubMed Web of Science ®Google Scholar
• ISAH AO, RAWLINS MD, BATEMAN DN: Clinical pharmacology of prochlorperazine in healthy young males. Br. J. Clin. Pharmacol. (1991) 32:677-684.
   PubMed Web of Science ®Google Scholar
• BRODIE MJ: Drug interaction in epilepsy. Epilepsia (1992) 33(Suppl. 1):13-22.
   Google Scholar
• SOLOMON S: Butalbital-containing agents: should they be banned? No. Curr. Pain Headache Rep. (2002) 6:147-150.
   PubMedGoogle Scholar
• WENZEL RG, SARVIS CA: Do butalbital containing products have a role in the management of migraine? Pharmacotherapy (2002) 22:1029-1035.
   PubMed Web of Science ®Google Scholar
• DROST ML, WALTER L: Blood and plasma concentrations of butalbital following single oral doses in man. J. Anal. Toxicol. (1988) 12:322-324.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD, MCCRORY DC: Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache (2001) 41:953-967.
   PubMed Web of Science ®Google Scholar
• WERMELING DP, BLOUIN RA, PORTER WH et al.: Pentobarbital pharmacokinetics in patients with severe head injury. Drug Intell. Clin. Pharm. (1987) 21:459-463.
   PubMedGoogle Scholar
• KUHLMANN J, MUCK W: Clinical pharmacological strategies to assess drug interaction potential during drug development. Drug Saf. (2001) 24:715-725.
   PubMed Web of Science ®Google Scholar
• DU-SOUICH P: In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can. J. Clin. Pharmacol. (2001) 8(3):153-161.
   PubMedGoogle Scholar
• VENKATAKRISHNAN K, VON-MOLTKE LL, OBACH RS, GREENBLATT DJ: Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr. Drug Metab. (2003) 4(5):423-459.
   PubMed Web of Science ®Google Scholar
• FERRARI A, OTTANI A, BERTOLINI A et al.: Adverse reactions related to drugs for headache treatment: clinical impact. Eur. J. Clin. Pharmacol. (2005) 60:893-900.
   PubMed Web of Science ®Google Scholar
• KANE GC, LIPSKY JJ: Drug–grapefruit juice interactions. Mayo Clin. Proc. (2000) 75:933-942
   PubMed Web of Science ®Google Scholar
• OBERMANN M, BARTSCH T, KATSARAVA Z: Medication overuse headache. Expert Opin. Drug Saf. (2006) 5:49-56.
   PubMed Web of Science ®Google Scholar
• GALLAGHER RM, KUNKEL R: Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache (2003) 43:36-43.
   PubMed Web of Science ®Google Scholar
• JORGENSEN HS, CHRISTENSEN HR, KAMPMANN JP: Interaction between digoxin and indomethacin or ibuprofen. Br. J. Clin. Pharmacol. (1991) 31:108-110.
   PubMed Web of Science ®Google Scholar
• STEWART CF, FLEMING RA, GERMAIN BF et al.: Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum. (1991) 34:1514-1520.
   PubMed Web of Science ®Google Scholar
• GAGLIARDI L: Possible indomethacin-aminoglycoside interaction in preterm infants (letter). J. Pediatr. (1985) 107:991-992.
   PubMed Web of Science ®Google Scholar
• RAGHEB M, BAN TA, BUCHANAN D et al.: Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J. Clin. Psychiatry (1980) 41:397-398.
   PubMed Web of Science ®Google Scholar
• LEONARD RJ, KNOTT PJ, RANKIN GO et al.: Phenytoin–salicylate interaction. Clin. Pharmacol. Ther. (1981) 29:56-60.
   PubMed Web of Science ®Google Scholar
• DAY RO, GEISSLINGER G, PAULL P et al.: The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers. Int. J. Clin. Pharmacol. Ther. (1995) 33:308-310.
   PubMed Web of Science ®Google Scholar
• CHAN TYK: Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann. Pharmacother. (1995) 9:1274-1283.
   Google Scholar
• SWEENEY KR, CHAPRON DJ, BRANDT JL et al.: Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin. Pharmacol. Ther. (1986) 40:518-524.
   PubMed Web of Science ®Google Scholar
• GASPARI F, VIGANO G, TOCATELLI M et al.: Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am. J. Kidney Dis. (1988) 11:338-342.
   PubMed Web of Science ®Google Scholar
• MINERS JO: Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin. Pharmacokinet. (1989) 17(5):327-344.
   PubMed Web of Science ®Google Scholar
• ABBOTT FS, KASSAM J, ORR JM et al.: The effect of aspirin on valproic acid metabolism. Clin. Pharmacol. Ther. (1986) 40:94-100.
   PubMed Web of Science ®Google Scholar
• Product information: Axert®, almotriptan. Ortho-McNeil Pharmaceutical, Raritan, NJ, USA (2004).
   Google Scholar
• Product information: Relpax®, eletriptan. Pfizer, New York, NY, USA (2002).
   Google Scholar
• Product information: Frova®, Frovatriptan. Endo Pharmaceuticals, Chadds Ford, PA, USA (2004).
   Google Scholar
• VAN HAARST AD, VAN GERVEN JMA, COHEN AF et al.: The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br. J. Clin. Pharmacol. (1999) 48:190-196.
   PubMed Web of Science ®Google Scholar
• GOLDBERG M, SCIBERRAS D, DE SMET M et al.: Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol, and metoprolol. Br. J. Clin. Pharmacol. (2001) 52:69-76.
   PubMed Web of Science ®Google Scholar
• DIXON CM, PARK GR, TARBIT MH: Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem. Pharmacol. (1994) 13:1253-1257.
   Google Scholar
• ROLAN P: Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90). Cephalalgia (1997) 17(Suppl. 18):21-27.
   PubMed Web of Science ®Google Scholar
• MINTON N, DIXON R, WILD M et al.: Drug interaction studies and metabolic enzyme characterisation with zolmitriptan (Zomig). Br. J. Clin. Pharmacol. (1999) 47:588.
   Web of Science ®Google Scholar
• Product information: Zomig® nasal spray, zolmitriptan nasal spray. AstraZeneca Pharmaceuticals, Wilmington DE, USA (2003).
   Google Scholar
• PECK RW, SEABER EJ, DIXON R et al.: The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br. J. Clin. Pharmacol. (1997) 44:595-599.
   PubMed Web of Science ®Google Scholar
• Product information: Cafergot®, ergotamine tartrate and caffeine. Novartis Phamaceuticals, East Hanover, NJ, USA (2002).
   Google Scholar
• MORTIER E, POUCHOT J, VINCENEUX P: Ergotism related to interaction between nelfinavir and ergotamine. Am. J. Med. (2001) 110:594.
   PubMedGoogle Scholar
• LEROY F, ASSEMAN P, PRUVOST P et al.: Dihydroergotamine–erythromycin-induced ergotism (letter). Ann. Intern. Med. (1988) 109:249.
   PubMed Web of Science ®Google Scholar
• Product information: Viramune®, nevirapine. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA (2004).
   Google Scholar
• Product information: NIRAVAM™ alprazolam. Schwarz Pharma, Milwaukee, WI, USA (2003).
   Google Scholar
• Product information: VFEND® voriconizole. Pfizer, New York, NY, (2005).
   Google Scholar
• PRESTON KL, GRIFFITHS RR, STITZER ML et al.: Diazepam and methadone interaction in methadone maintenance. Clin. Pharmacol. Ther. (1984) 36(4):534-541.
   PubMed Web of Science ®Google Scholar
• GUREVITZ SL: Erythromycin: drug interactions. Dent. Hyg. (1997) 71(4):159-161.
   Google Scholar
• COBB MN, DESAI J, BROWN LS Jr et al.: The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin. Pharmacol. Ther. (1998) 63:655-662.
   PubMed Web of Science ®Google Scholar
• IRIBARNE C, PICART D, DREANO Y et al.: In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam. Clin. Pharmacol. (1998) 12(2):194-199.
   PubMed Web of Science ®Google Scholar
• FUHR U: Drug interactions with grapefruit juice. Drug Saf. (1998) 18(4):251-272.
   PubMed Web of Science ®Google Scholar
• KHALSA J, GENSER S, VOCCI F et al.: The challenging interactions between antiretroviral agents and addiction drugs. Am. Clin. Lab. (2002) 21(3):10-13.
   PubMedGoogle Scholar
• TONG TG, POND SM, KREEK MJ et al.: Phenytoin-induced methadone withdrawal. Ann. Intern. Med. (1981) 94(3):349-351.
   PubMed Web of Science ®Google Scholar
• NIEMI M, BACKMAN JT, FROMM MF et al.: Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. (2003) 42(9):819-850.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ JS, WELLS BG, CARSON WH: Interactions between antipsychotic and antihypertensive drugs. Ann. Pharmacother. (1995) 29(6):603-609.
   PubMed Web of Science ®Google Scholar
• EICH-HOCHLI D, OPPLIGER R, GOLAY KP et al.: Methadone maintenance treatment and St. John’s Wort. Pharmacopsychiatry (2003) 36(1):35-37.
   PubMed Web of Science ®Google Scholar
• GUAY DR, MEATHERALL RC, CHALMERS JL et al.: Ranitidine does not alter pethidine disposition in man. Br. J. Clin. Pharmacol. (1985) 20:55-59.
   PubMed Web of Science ®Google Scholar
• Product information: Demerol®, meperidine hydrochloride. Sanofi-Synthelabo, New York, NY, USA (2003).
   Google Scholar
• POND SM, KRETSCHZMAR KM: Effect of phenytoin on meperidine clearance and normeperidine formation. Clin. Pharmacol. Ther. (1981) 30:680-686.
   PubMed Web of Science ®Google Scholar
• PISCITELLA S, KRESS D, BERTZ R et al.: The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy (2000) 20(5):549-553.
   PubMed Web of Science ®Google Scholar
• LAUGENSEN S, ENGGAARD TP, PEDERSEN RS, SINDRUP SH, BROSEN K: Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin. Pharmacol. Ther. (2005) 77(4):312-323.
   PubMed Web of Science ®Google Scholar
• Product information: Ultram®, tramadol hydrochloride. Ortho-McNeil Pharmaceutical, Raritan, NJ, USA (2001).
   Google Scholar
• MADSEN H, RASMUSSEN JM, BROSEN K: Interaction between tramadol and phenprocoumon (letter). Lancet (1997) 350:637.
   PubMed Web of Science ®Google Scholar
• Product information: Norvir®, ritonavir. Abbott Laboratories, North Chicago, IL, USA (2000).
   Google Scholar
• KIRCH W, JANISCH HD, SANTOS SR et al.: Effect of cisapride and metoclopramide on digoxin bioavailability. Eur. J. Drug. Metab. Pharmacokinet. (1986) 2:249-250.
   Google Scholar
• Product information: Rapamune®, sirolimus. Wyeth Pharmaceuticals, Philadelphia, PA, USA (2005).
   Google Scholar
• PRESCOTT WA, CALLAHAN BL, PARK JM: Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy (2004) 24(4):532-537.
   PubMed Web of Science ®Google Scholar
• RIVERA-CALIMLIM L, NASRALLAH H, STRAUSS L et al.: Clinical response and plasma levels: effect of dose, dosage schedules and drug interaction on plasma chlorpromazine levels. Am. J. Psychiatry (1976) 133:646-652.
   PubMed Web of Science ®Google Scholar
• PEET M, MIDDLEMISS SN, YATES RA: Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. Br. J. Psychiatry (1981) 138:112-117.
   Google Scholar
• Product information: Cymbalta®, duloxetine. Eli Lilly, Indianapolis, IN, USA (2004).
   Google Scholar
• LOGA S, CURRY S, LADER M: Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. Br. J. Clin. Pharmacol. (1975) 2:197-208.
   PubMed Web of Science ®Google Scholar
• O’REILLY RA, TRAGER WF, MOTLEY CH et al.: Interaction of secobarbital with warfarin pseudoracemates. Clin. Pharmacol. Ther. (1980) 28:187-195.
   PubMed Web of Science ®Google Scholar
• GAREY KW, AMSDEN GW, JOHNS CA: Possible interaction between imipramine and butalbital. Pharmacotherapy (1997) 17:1041-1042.
   PubMed Web of Science ®Google Scholar
• GAMBERTOGLIO JG, HOLFORD NH, KAPUSNIK JE et al.: Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int. (1984) 25:119-123.
   PubMed Web of Science ®Google Scholar
• Product information: Mycobutin®, rifabutin. Adria Laboratories, Columbus, Ohio, USA (1996).
   Google Scholar
• FRINK EJ JR, GHANTOUS H, MALAN P et al.: Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. Anesth. Analg. (1992) 74:231-235.
   PubMed Web of Science ®Google Scholar
• PALADINO JA, BLUMER NA, MADDOX RR: Effect of secobarbital on theophylline clearance. Ther. Drug. Monit. (1983) 5:135-139.
   PubMed Web of Science ®Google Scholar
• Product information: Nipolept®, zotepine. Klinge Pharma GmbH, Munich, Germany (1994).
   Google Scholar

Websites

• http://ahsnet.org/guidelines.phpPharmacological Management of Acute Attacks. US Headache Consortium (2000).
   Google Scholar
• http://www.bash.org.ukBRITISH ASSOCIATION FOR THE STUDY OF HEADACHE: Guidelines for all doctors in the diagnosis and management of migraine and tension-type headache, 2nd edition (revised August 2004).
   Google Scholar